Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy.

Oncotarget - 11 Jul 2017

Kasper Stefan, Reis Henning, Ziegler Sophie, Nothdurft Silke, Mueller Andre, Goetz Moritz, Wiesweg Marcel, Phasue Jeannette, Ting Saskia, Wieczorek Sarah, Even Anna, Worm Karl, Pogorzelski Michael, Breitenbuecher Sandra, Meiler Johannes, Paul Andreas, Trarbach Tanja, Schmid Kurt Werner, Breitenbuecher Frank, Schuler Martin

Abstract excerpt

Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR), cetuximab and panitumumab, are a mainstay of metastatic colorectal cancer (mCRC) treatment. However, a significant number of patients suffer from primary or acquired resistance. RAS mutations are negative predictors of clinical efficacy of anti-EGFR antibodies in patients with mCRC. Oncogenic RAS activates the MAPK and PI3K/AKT pathways,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Genes, ras

Share to Mitogen-Activated Protein Kinases

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins c-akt

Share to Proto-Oncogene Proteins c-bcl-2

Source

Open in PubMed Open full text

Identifiers

PMID: 28507280
DOI: 10.18632/oncotarget.17438
PMCID: PMC5542236

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy.PMID 28507280Read ↗

Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.Semantic proximity Read ↗

Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer.Semantic proximity Read ↗

Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.Semantic proximity Read ↗

Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK.Semantic proximity Read ↗

Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.Semantic proximity Read ↗

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.Semantic proximity Read ↗

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.Semantic proximity Read ↗

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.Semantic proximity Read ↗

Towards a unified model of RAF inhibitor resistance.Semantic proximity Read ↗

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.Semantic proximity Read ↗

c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.